People living with lupus carry a heart risk that is easy to overlook. Young women with the disease are far more likely to have a heart attack than women of the same age without it. A study in Arthritis Care and Research, picked up by the health press on 21 September 2026, adds a practical twist: the amount of hydroxychloroquine actually circulating in the blood, not just the dose written on the prescription, tracked with how that cardiovascular risk moved over the following year or two. That number comes from an ordinary blood test. This article explains what it measures, why it varies so much from one person to the next, and what a low result is really telling you.
What the new lupus study looked at
Researchers led by the Yale Lupus Programme followed 248 adults with systemic lupus erythematosus. For each person they calculated a cardiovascular risk score with PREVENT, a tool from the American Heart Association that combines cholesterol, blood pressure, kidney measures and other routine data. They recalculated the score a year later, then compared how it had moved against two things: the hydroxychloroquine blood level, and how consistently the person refilled the prescription.
Participants whose blood level stayed very low, and who refilled less consistently, saw their risk score climb over one to two years. The shift was small in absolute terms. It stood out because the group was young and mostly sat in the low or intermediate risk band to begin with, where scores are not expected to move much at all. The authors describe this as a signal to confirm in a larger cohort, not a settled fact.
What a hydroxychloroquine blood level measures
Hydroxychloroquine is the backbone treatment in lupus, taken daily and often for life. Most lab work in lupus hunts for signs of the disease itself. Our blood marker library covers the antinuclear antibodies (ANA) blood test. Another page explains the complement C3 blood test. A hydroxychloroquine level is different in kind: it measures the medicine, not the illness. Laboratories call this therapeutic drug monitoring, and it answers a question no disease marker can answer, which is how much of the drug has actually reached the bloodstream.
The result comes back in nanograms per millilitre (ng/mL). Rheumatology teams generally work with a therapeutic window of roughly 750 to 1,150 ng/mL. Below that window the drug is present but thin on the ground. A result under about 200 ng/mL is read as a sign that doses are regularly going missing, rather than as a metabolic quirk.
Why two people on the same dose land on different numbers
Dosing is weight-based, usually capped at 5 mg per kilogram per day. Weight alone does not predict where the blood level ends up.
Kidney function
The kidneys help clear hydroxychloroquine. When filtration slows, the drug accumulates and the level can climb above the window even on a standard dose. This is why teams read the result alongside kidney numbers. Our library explains the estimated glomerular filtration rate (eGFR), and a recent article covers the link between kidney function tests and heart disease.
Missed doses
Daily lifelong medication is hard to sustain, and the blood level is unforgiving about gaps. A quality improvement project at a large American centre tested 170 patients and found the large majority of them sitting below the therapeutic window, with a sizeable minority down in the very low range.
Body size and metabolism
Absorption, distribution into tissue and individual metabolism all shift the final figure. Two people on an identical milligram dose can land hundreds of nanograms apart.
How the numbers are usually grouped
Laboratories and rheumatology teams tend to sort results into four bands. The table below is a reading aid, not a rulebook: only the prescribing clinician can act on a result.
| Blood level | Usual reading | What the team reviews next |
|---|---|---|
| Under 200 ng/mL | Severe non-adherence range | Practical barriers to taking the tablet every day, side effects, cost, routine |
| 200 to 749 ng/mL | Below the therapeutic window | Partial adherence, absorption, dosing, and current disease activity |
| 750 to 1,150 ng/mL | Therapeutic window | Exposure looks adequate, routine follow-up continues |
| Above 1,150 ng/mL | Above the therapeutic window | Dose, body weight and kidney filtration, especially if filtration has fallen |
Where the heart risk fits in
Lupus drives chronic inflammation, and inflammation accelerates the build-up of plaque inside arteries. Hydroxychloroquine tempers that inflammation, and it also has modest effects on cholesterol and on clotting. A large observational analysis has associated its use with fewer cardiovascular events overall. What the new work adds is granularity: it is not simply whether the drug is prescribed, but whether enough of it is present in the blood, that appears to track with risk.
That is also why the standard cardiovascular panel still matters in lupus. Another guide details the LDL cholesterol blood test, the marker most often used to gauge arterial risk.
Latest scientific advances
Three recent publications sit behind this story, and all three point the same way.
- A prospective cohort of 247 patients, published in Arthritis Care and Research in April 2026, tracked close to a thousand clinic visits. Patients whose level sat below the therapeutic window had markedly higher odds of active lupus, and each step upward in level at a visit went with lower odds of a flare. What it changes for you: the number is not bookkeeping, it moves with how the disease behaves.
- A quality improvement report in Lupus Science and Medicine, published in June 2026, lifted testing from a small fraction of eligible patients to roughly one in seven, and found that most of those tested were below the therapeutic window. What it changes for you: if nobody measures, a low level stays invisible.
- A 2025 review in a French internal medicine journal set out how to interpret the figure, including the threshold below which poor adherence becomes the most likely explanation, and restated that eye screening remains part of long-term follow-up. What it changes for you: the level is read alongside eye checks, never instead of them.
All three are observational studies. None of them show that raising a blood level prevents a heart attack. They show that the number carries information worth having.
When to talk to your care team
- You have lupus, you take hydroxychloroquine, and your level has never been measured.
- Your result came back below the therapeutic window.
- Your kidney numbers have changed since your dose was set.
- You have been missing doses and have not mentioned it to anyone.
- You notice chest pain, breathlessness or new vision changes. Vision changes need prompt review, because long-term hydroxychloroquine carries a small cumulative risk to the retina.
Never change or stop hydroxychloroquine on your own. Stopping it raises the risk of a severe flare.
Glossary
- Hydroxychloroquine (HCQ): an antimalarial medicine used as the backbone long-term treatment of lupus.
- Therapeutic drug monitoring: measuring a medicine in the blood to check exposure and guide dosing.
- Therapeutic window: the range of blood concentrations where a drug works well at acceptable risk.
- ng/mL: nanograms per millilitre, the unit used for hydroxychloroquine levels.
- ASCVD: atherosclerotic cardiovascular disease, the artery narrowing behind most heart attacks and strokes.
- PREVENT: an American Heart Association calculator that estimates cardiovascular risk from routine clinical and laboratory data.
- Flare: a period when lupus activity increases.
Frequently asked questions
Is a hydroxychloroquine blood level a routine test?
Not yet. It is available in many hospital laboratories but ordered far less often than disease markers. Use is rising as the evidence accumulates.
Do I need to fast before the test?
No. It is a standard venous blood draw. Timing relative to your last dose can matter, so follow the instructions your team gives you.
Does a low level mean I am doing something wrong?
No. Kidney function, absorption and metabolism all move the number. A low result is information, not a verdict.
Can a high level be a problem?
A level above the window is usually a prompt to review the dose, especially when kidney filtration has fallen. Your team decides.
Does this study mean hydroxychloroquine protects the heart?
It suggests an association between maintaining an adequate blood level and a slower rise in estimated cardiovascular risk. It does not prove cause and effect.
Sources
- Centers for Disease Control and Prevention, Lupus Basics
- MedlinePlus, National Library of Medicine, Hydroxychloroquine
- Yale School of Medicine, Adhering to Common Lupus Treatment Lowers Risk of Heart Issues, 3 September 2026
- Garg S. et al., Optimizing Hydroxychloroquine Blood Levels and Long-Term Hydroxychloroquine Intake Could Lower Atherosclerotic Cardiovascular Disease Risk in Systemic Lupus Erythematosus, Arthritis Care and Research, 2026
- Patel J. J. et al., Real-World Longitudinal Data on the Impact of Hydroxychloroquine Blood Level Monitoring on Lupus Outcomes, Arthritis Care and Research, April 2026 (indexed in PubMed)
- Saleh Z. et al., Increasing the utilisation of hydroxychloroquine blood level testing in lupus, Lupus Science and Medicine, June 2026 (indexed in PubMed)
- Trefond L., Hydroxychloroquine in systemic lupus erythematosus: key updates, La Revue de medecine interne, 2025 (indexed in PubMed)
Other articles
- Our library sets out the basics of lupus.
- A separate page details the autoimmune panel.
- We also publish our guide to reading blood test results.
- Our blood marker library covers the antinuclear antibodies (ANA) blood test.
- Another page explains the complement C3 blood test.
- Our library explains the estimated glomerular filtration rate (eGFR).
- A recent article covers the link between kidney function tests and heart disease.
- Another guide details the LDL cholesterol blood test.
Understand your lab results with AI DiagMe
A hydroxychloroquine level never travels alone on a lab report. It sits next to kidney markers, a lipid panel and the immune markers that follow lupus, and the meaning is in how those numbers move together. AI DiagMe reads your laboratory report and explains, marker by marker, what each value means and which ones deserve a conversation with your doctor. Understand your lab results with AI DiagMe.
